Overview

ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study is a multicentric randomized trial evaluating the efficacy of the combination R-ACVBP in patients 18 to 65 years with low risk localized diffuse large B-cell lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
Lymphoma Study Association
Collaborator:
Amgen
Treatments:
Cyclophosphamide
Doxorubicin
Rituximab